StemoniX

What StemoniX does

StemoniX, founded in 2014 and headquartered in Maple Grove, Minnesota, is a biotechnology company that develops human brain organoid technology for preclinical drug safety and efficacy assessment. Operating commercially as 28bio, the company serves pharmaceutical and biotechnology companies engaged in CNS drug development, addressing the high attrition rates in neurological drug trials caused by inadequate preclinical models. With 11-50 employees, StemoniX targets a specific translational failure point in neuroscience: the poor predictive performance of animal models and 2D cell-based assays for clinical CNS outcomes.

The company's core technology is built on induced pluripotent stem cell (iPSC)-derived 3D neural cultures that produce brain organoids capable of measuring human neural activity. Its product portfolio comprises CNS-3D Brain Organoids (for predicting clinical seizure liability), CNS-3D Inflammatory Organoids (for neuroinflammatory disease modeling), CNS-3D Myelinated Organoids (for remyelination drug testing), and a CNS-3D Alzheimer's Model (for neurodegeneration research), complemented by dedicated CNS-3D and PNS-3D service offerings. The technology is validated through the Endurance Study, a retrospective analysis using clinical outcomes from 120,551 patients, which reported 83% sensitivity and 89% specificity in seizure liability prediction — performance positioned as 13x more predictive than animal models and aligned with regulatory agency guideline recommendations.

StemoniX generates revenue through B2B direct sales to enterprise pharmaceutical and biotechnology customers, with pricing not publicly disclosed. Go-to-market is anchored on scientific content marketing — webinars, scientific publications, application notes, and industry events such as 28bioLIVE — rather than broad digital demand-gen, which is consistent with a high-touch, validation-driven preclinical services sale. The company has raised approximately $33.2 million in disclosed funding across multiple rounds through 2020, with the largest being a $14.4 million Series A in February 2019 led by Brightstone Venture Capital, alongside participation from Alumni Ventures, Mayo Clinic, Keshif Ventures, and Seed San Diego. No revenue, customer logo, or partnership data has been publicly disclosed.

Name

StemoniX

Website

https://stemonix.com

Company type

Private

Founded year

2014

Headcount range

11–50 employees

Short description

StemoniX (operating as 28bio) develops iPSC-derived 3D brain organoids for preclinical CNS and PNS drug safety and efficacy testing, serving pharmaceutical and biotechnology companies in neurological drug development.

Ownership category

akta.pro rank

Product category

Preclinical Drug Safety Testing

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industry

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)

Keywords

• Brain organoid technology
• Preclinical safety testing
• Neurotoxicity testing services
• Drug discovery platforms
• Stem cell biotechnology

Headquarters

HQ city

Maple Grove

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels5 records

Core offering

StemoniX (operating as 28bio) develops and commercializes human iPSC-derived 3D brain organoid products and related testing services for preclinical safety and efficacy assessment in drug development. The company's core offerings include CNS-3D Brain Organoids, disease-specific organoid models (inflammatory, myelinated, Alzheimer's), and dedicated CNS-3D and PNS-3D testing services used by pharmaceutical and biotech companies to predict clinical seizure liability, neurotoxicity, and peripheral neuropathy.

Product overview

28bio offers a portfolio of CNS-3D organoid products and services designed for preclinical safety and efficacy assessment in drug development. The core offering centers on CNS-3D Brain Organoids, which use human iPSC-derived neural cultures to predict clinical outcomes like seizure liability. Additional products include CNS-3D Inflammatory Organoids for disease modeling, CNS-3D Myelinated Organoids for remyelination studies, and CNS-3D Alzheimer's Model for neurodegeneration research. The portfolio is supported by dedicated CNS-3D and PNS-3D service offerings. The Endurance Study demonstrated that CNS-3D Brain Organoids achieve 83% sensitivity and 89% specificity in predicting clinical seizure liability, outperforming animal models by 13x.

Differentiator

Problem solved

Functional benefit

Products and services

• CNS-3D Brain Organoids Human brain organoids derived from iPSC technology that measure human neural activity to predict clinical seizure liability; demonstrated 83% sensitivity, 89% specificity, and 13x better predictive performance than animal models in the Endurance Study. Sold to pharmaceutical and biotech companies for preclinical CNS safety testing.
• CNS-3D Inflammatory Organoids 3D brain organoid model designed for neuroinflammatory disease modeling, enabling measurement of human neural activity linked to clinical safety and efficacy. Targeted at pharmaceutical researchers studying neuroinflammation.
• CNS-3D Myelinated Organoids Specialized brain organoid model for remyelination drug efficacy testing, enabling evaluation of therapeutic candidates for demyelinating diseases such as multiple sclerosis.
• CNS-3D Alzheimer's Model Brain organoid model specifically developed for Alzheimer's disease modeling, supporting drug discovery and efficacy assessment for neurodegenerative disease therapeutics.
• CNS-3D Services Service offerings centered on the CNS-3D technology platform for preclinical safety assessment, CNS toxicity testing, and efficacy evaluation performed for pharmaceutical and biotech clients.
• PNS-3D Services Peripheral nervous system 3D testing services for drug-induced peripheral neuropathy testing, providing predictive human neural activity measurements to pharmaceutical clients.

Quantifiable outcome

• 83% sensitivity and 89% specificity predicting clinical seizure liability
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Hesperos: Hesperos builds multi-organ microphysiological systems and organoid-based assays for preclinical drug testing, including neurological applications, making it a direct peer in human-relevant preclinical safety and efficacy services.
• Emulate: Emulate's organ-on-chip platform provides human-relevant in vitro models for toxicity and disease modeling across multiple tissues, overlapping with 28bio's CNS and PNS preclinical testing value proposition.
• Axol Bioscience: Axol Bioscience supplies iPSC-derived neural cells and custom neurological disease models for drug discovery, directly competing in the iPSC-based CNS modeling and assay market.
• InSphero: InSphero develops 3D organoid and spheroid models for preclinical drug safety and efficacy testing, including neurotoxicity assays, competing head-to-head with CNS-3D Brain Organoids in the human-relevant preclinical services market.
• Newcells Biotech: Newcells Biotech offers iPSC-derived cell and organoid models, including neural models, for drug discovery and toxicity testing — a closely comparable iPSC-based preclinical platform serving pharma and biotech customers.

Broad incumbents

• WuXi AppTec: WuXi AppTec is a large global CRO/CDMO providing preclinical safety and efficacy services, including CNS testing, and is a broad incumbent competing for outsourced neuroscience drug development work.
• Charles River Laboratories: Charles River is a global CRO offering extensive preclinical CNS safety and efficacy testing services. While not organoid-specialized, it competes for the same pharma preclinical testing wallet and is a natural channel partner or competitive threat.

Emerging players

• Prellis Biologics: Prellis Biologics uses 3D bioprinting and organoid technology for antibody discovery and human tissue models, intersecting with 28bio's organoid-based drug discovery applications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/StemoniX
• LinkedInlinkedin.com/company/stemonix

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds11 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StemoniX